Loading…
Clene Inc. is projected to rise to $7.19 by 2027, a +43% move from its current price of $5.02. CLNN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $4.85 | $5.02 | $5.19 | +0.01% |
| Aug 6 | $4.78 | $5.02 | $5.26 | +0.01% |
| Aug 7 | $4.73 | $5.02 | $5.32 | +0.02% |
| Aug 8 | $4.68 | $5.02 | $5.37 | +0.02% |
| Aug 9 | $4.65 | $5.02 | $5.42 | +0.03% |
| Aug 10 | $4.61 | $5.02 | $5.46 | +0.03% |
| Aug 11 | $4.58 | $5.02 | $5.49 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.58 | $5.02 | $5.49 | +0.04% |
| Week 2 | $4.42 | $5.02 | $5.71 | +0.08% |
| Week 3 | $4.29 | $5.02 | $5.87 | +0.12% |
| Week 4 | $4.19 | $5.02 | $6.02 | +0.16% |
| Week 5 | $4.10 | $5.02 | $6.15 | +0.20% |
| Week 6 | $4.03 | $5.03 | $6.28 | +0.24% |
| Week 7 | $3.96 | $5.03 | $6.39 | +0.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Clene Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is headquartered in Salt Lake City, Utah, and operates in the Consumer Defensive sector.
Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS). The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles.
Clene Inc. is a clinical-stage pharmaceutical company in the Consumer Defensive sector.
Its shares trade at $4.99, with a market capitalization of $63.76M, and it ranks 4234.
The forecast paints a long-run bullish trajectory. The 2026 average price is $4.99, rising through the years to an average of $8.33 by 2030, $18.84 by 2040, and $30.57 by 2050, with a long-run maximum implied around $57.54 and a long-run minimum around $3.92 for 2026. The 2050 forecast implies a return of 512.7 and a bullish sentiment, with yearly progressions showing continued upside (e.g., 2027 avg $6.94; 2028 $7.64; 2029 $7.81; 2031 $8.43; 2032 $9.18; 2033 $11.17; 2034 $12.42; 2035 $13.52; 2040 $18.84).
A major floor 26.1% below — a decisive break under it would weaken the trend.
The nearest floor, 5.9% below — buyers have tended to step in here.
The nearest ceiling, 27.4% above — a clean break opens room to run.
A major ceiling 61.3% above — clearing it would confirm fresh momentum.
Key CLNN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLNN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.05 | Sell | $5.08 | Sell |
| MA 10 | $5.35 | Sell | $5.29 | Sell |
| MA 20 | $5.72 | Sell | $5.55 | Sell |
| MA 50 | $5.91 | Sell | $5.82 | Sell |
| MA 100 | $6.02 | Sell | $5.93 | Sell |
| MA 200 | $6.38 | Sell | $5.93 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.45 | Neutral |
| Stoch RSI (14) | 34.15 | Neutral |
| CCI (20) | -117.41 | Sell |
| Williams %R (14) | -79.59 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | -16.61 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 20.41 | Neutral |
| TRIX (15) | -0.40 | Sell |
| Awesome (5,34) | -0.77 | Sell |
| Ultimate (7,14,28) | 27.25 | Buy |
| Momentum (10) | -0.90 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 4.76 | Buy |
| ADX (14) | 17.56 | Neutral |
| ATR (14) | 0.18 | Info |
The 30-day technical picture is bearish, with RSI14 at 40.
The near-term moving averages sit at SMA50 of $6.09 and SMA200 of $6.48, creating a near-term drift below key trend lines. Support is indicated at $5.46 and resistance at $6.39, suggesting the stock could test these levels within the 30-day window. The 30-day trading range runs from $4.13 to $6.03, highlighting limited upside against current price pressure and notable volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.92 | $5.02 | $7.21 | 0% | Neutral | |
| $5.60 | $7.19 | $9.83 | +43% | Bullish | |
| $5.88 | $7.83 | $11.20 | +56% | Bullish | |
| $5.77 | $7.92 | $11.74 | +58% | Bullish | |
| $5.96 | $8.39 | $12.82 | +67% | Bullish | |
| $5.69 | $8.22 | $12.88 | +64% | Bullish | |
| $6.08 | $8.99 | $14.40 | +79% | Bullish | |
| $7.35 | $11.09 | $18.14 | +121% | Bullish | |
| $7.99 | $12.32 | $20.53 | +146% | Bullish | |
| $8.65 | $13.60 | $23.06 | +171% | Bullish | |
| $10.71 | $18.46 | $33.66 | +268% | Bullish | |
| $14.26 | $28.94 | $58.53 | +477% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.92 | $5.02 | $6.25 | +0.00% |
| September 2026 | $4.32 | $5.15 | $6.33 | +2.68% |
| October 2026 | $4.19 | $5.04 | $6.28 | -2.11% |
| November 2026 | $4.38 | $5.30 | $6.68 | +5.23% |
| December 2026 | $4.65 | $5.66 | $7.21 | +6.78% |
Click any year to see its month-by-month CLNN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CLNN could reach as high as $7.21, with a base case around $5.02 and support toward $3.92 — roughly 0% from $5.02. Price action looks broadly range-bound.
Expect CLNN to range from $5.60 to $9.83 through 2027. The $7.19 average target implies a +43% move from current prices. That is up +43% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The CLNN price prediction for 2028 points to an average of $7.83 (low $5.88, high $11.20) — a potential gain of +56% on today's $5.02. Momentum favours further upside here.
In 2029, CLNN is projected to trade between $5.77 and $11.74, averaging $7.92 — a potential gain of +58% from today's $5.02. That is up +1% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Clene Inc.'s 2030 outlook centres on $8.39, within a $5.96 to $12.82 range. That is up +6% on the projected 2029 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2031, CLNN could reach as high as $12.88, with a base case around $8.22 and support toward $5.69 — roughly +64% from $5.02. Buyers look set to stay in control over this stretch.
Expect CLNN to range from $6.08 to $14.40 through 2032. The $8.99 average target implies a +79% move from current prices. That is up +9% on the projected 2031 average. Momentum favours further upside here.
The CLNN price prediction for 2033 points to an average of $11.09 (low $7.35, high $18.14) — a potential gain of +121% on today's $5.02. Buyers look set to stay in control over this stretch.
In 2034, CLNN is projected to trade between $7.99 and $20.53, averaging $12.32 — a potential gain of +146% from today's $5.02. That is up +11% on the projected 2033 average. Momentum favours further upside here.
Clene Inc.'s 2035 outlook centres on $13.60, within a $8.65 to $23.06 range. That is up +10% on the projected 2034 average. That marks a +171% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, CLNN could reach as high as $33.66, with a base case around $18.46 and support toward $10.71 — roughly +268% from $5.02. Momentum favours further upside here.
Expect CLNN to range from $14.26 to $58.53 through 2050. The $28.94 average target implies a +477% move from current prices. That is up +57% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLNN today (≈ 199.401795 CLNN) could be worth
$5,770.95
+$4,770.95 (+477%) by 2050 · US Dollar
Based on the average projected CLNN price of $28.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLNNwould be worth at today's price.
$1,000 invested in CLNN on Jul 31, 2025 (≈ 282.485879 CLNN) would be worth
$1,416.67
+$416.67 (+41.7%) today · 1.42× · US Dollar
Based on a CLNN entry price of $3.54 vs. today's $5.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.39 | $930.43 | -7.0% |
| 1 month ago | $6.13 | $818.11 | -18.2% |
| 3 months ago | $6.14 | $816.78 | -18.3% |
| 6 months ago | $4.04 | $1,241.34 | +24.1% |
| 1 year ago | $3.54 | $1,416.67 | +41.7% |
| All time (5.0y) ago | $187.4 | $26.76 | -97.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLNN forecast.
Our base-case forecast reaches $10.00 around 2033.
Implied market cap at $10.00: $127.78M
The multi-year forecast shows a bullish path with meaningful upside through the 2030s and 2040s. The 2026 average is $4.99 with a neutral sentiment, and then sentiment shifts to bullish in subsequent years. The forecast progression includes 2027 avg $6.94 (ROI 39), 2028 avg $7.64 (ROI 53.1), 2029 avg $7.81 (ROI 56.5), 2030 avg $8.33 (ROI 66.9), 2031 avg $8.43 (ROI 68.8), 2032 avg $9.18 (ROI 84), 2033 avg $11.17 (ROI 123.9), 2034 avg $12.42 (ROI 149), 2035 avg $13.52 (ROI 170.9), 2040 avg $18.84 (ROI 277.5), and 2050 avg $30.57 (ROI 512.7).
The forecast is bullish across 2027 through 2050, with higher potential upside at later dates. These are estimates, not guarantees, and actual results may vary depending on market conditions and company developments.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $8.33, with a minimum of $6.13 and a maximum of $12.22. The forecast also lists an ROI of 66.9 and a bullish sentiment for 2030.
The outlook from 2027 onward is bullish with rising averages and positive ROIs (e.g., 2027 avg $6.94 and 39, 2030 avg $8.33 and 66.9, 2040 avg $18.84 and 277.5, 2050 avg $30.57 and 512.7). However, 2026 is neutral, and these figures are estimates, not guarantees.
Yes. The forecast max reaches $19.68 in 2034 and $21.75 in 2035, with earlier years showing values above $15 (e.g., 2033 max $17.41). This suggests a path to $15 is within the modeled upside.
The current price is $4.99. The 30-day range is $4.13 to $6.03, with support at $5.46 and resistance at $6.39, and a bearish near-term sentiment (RSI 14 at 40). The SMA50 is $6.09 and the SMA200 is $6.48, indicating resistance near recent highs.
The model shows a bullish long-term path, with 2050 average price at $30.57 and a 2050 ROI of 512.7, following an upward progression from 2027 onward (e.g., 2027 avg $6.94; 2030 avg $8.33; 2040 avg $18.84). These are estimates and not guaranteed.
Clene Inc. Community Discussion
0Share your Clene Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.